Publication:
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Thumbnail Image
Identifiers
URI: https://hdl.handle.net/20.500.12105/23626
DOI: 10.1038/s41408-023-00805-x
Full text access: https://hdl.handle.net/20.500.13003/18923
SCOPUS: 2-s2.0-85149595607
WOS: 950825100001

Publication date

2023-03-07

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publishers

Metrics
Google Scholar
Export
MarcXML METS

Research Projects

Organizational Units

Journal Issue

Abstract

Description

Keywords

MeSH Terms

Multiple Myeloma Antibodies, Monoclonal Humans Neoplasms, Plasma Cell Dexamethasone

DeCS Terms

Dexametasona Humanos Neoplasias de Células Plasmáticas Mieloma Múltiple Anticuerpos Monoclonales

Bibliographic citation

Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, et al. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 Mar 7;13(1):33.

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
IBSAL - Instituto de Investigación Biómedica de Salamanca (Castilla y León)
IDIBAPS - Instituto de Investigaciones Biomédicas August Pi i Sunyer (Cataluña)
IDIBELL - Instituto de Investigación Biomédica de Bellvitge (Cataluña)
IiSGM - Instituto de Investigación Sanitaria Gregorio Marañón (Madrid)

Publisher version

https://doi.org/10.1038/s41408-023-00805-x

Related dataset

Related publication

Document type

letter to the editor